VCYT Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 6.02%, SMA50 -3.47%, SMA200 13.22%). The stock’s 14-day RSI is 54.98 (neutral), while the ATR of 1.7 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.59% below its high and over 71.38% above its low. Average 10-day trading volume of 1.47 million shares is slightly above the 3-month average of 1.30 million, indicating heightened recent market interest.

Veracyte, Inc. has 80.39 million shares outstanding. The public float is 79.88 million shares, elevated short interest at 10.08% of float. This equals 6.86 million shares. The short ratio is 5.5 days. Institutional investors hold 114.02% of the float. Insiders own 0.49%. Stapley Marc holds 440.49 thousand shares, Chambers Rebecca has 166.02 thousand shares and Febbo Phillip G. has 133.05 thousand shares. Over the past six months, insider transactions show net selling. They sold 207.24 thousand shares across 13 transactions.

Veracyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $39.57. This means the shares are trading near this model’s fair value.

Veracyte, Inc. (NASDAQ:VCYT) closed at $39.80 USD, losing -$0.77 (-1.91%) from the previous close of $40.57. The stock is currently mid-range between its 52-week high and low $29.45 and $60.91. With a market capitalization of about $3.18 billion, Veracyte, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.93). Key stats such as the average daily volume over the past year has been around 1.29 million shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, Veracyte, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Marc Stapley, the company employs approximately 755 people and listed since October 29, 2013. Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

Veracyte, Inc. trades at a P/E ratio of 27.92, slightly below the S&P 500 average, with a price-to-sales ratio of 5.71 and a price-to-book ratio of 2.31 suggesting the stock is closer to book value. The P/FCF stands at 19.39, also above market averages.

Wall Street analysts project EPS growth of 4.03% annually over the next five years. The latest quarter delivered EPS of $0.54. The next quarter is forecast at $0.34. Next year's EPS is expected at $62.14. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 16 Buy ratings, 6 Hold ratings, 0 Sell rating and 5 Strong Sell ratings. Price targets range from $69.00 to $40.00. The high target offers 73.37% upside. The low target suggests 0.5% downside. The mean target is $50.67. This offers 27.31% upside. Veracyte, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended July 30, 2026, missed forecasts by 26.2%. The prior quarter beat by 52.94%. Over the last six quarters, Apple has recorded several small beats. These include 55.0% in May 07, 2025.

Our AI price prediction model suggests that Veracyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.24%, with price expected at $38.51 by October 02, 2026, within a range of $36.67 to $40.48 3-Month Outlook: Projected fall of -12.74%, reaching $34.73 by December 17, 2026, with a range of $31.02 to $37.32. 1-Year Outlook: Projected gain of 21.91%, with price at $48.52 by September 17, 2027, within a range of $46.54 to $50.86.

Veracyte, Inc. (NASDAQ:VCYT) shares are flat -0.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Veracyte, Inc. trading at a premium to the broader market with a P/E of 27.92. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $43.77, suggesting 9.97% upside. Our AI forecast model points to short-term weakness (-3.24% over two weeks), a medium-term fall (-12.74% over three months), and a longer-term gain (21.91% over one year), with expected trading ranges indicating moderate volatility.